Skip to main content

Table 2 COVID-19 outcomes in Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis (PsA) patients

From: COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data

 

Total (N = 207) *

axSpA (N = 132)

PsA (N = 75)

p

Symptom duration (days), mean (SD)

13.3 (9.3)

9.9 (10.1)

11.1 (9.6)

0.412c

Contact with a confirmed case, n (%)

114 (55.0)

73 (55.0)

41 (54.7)

0.495

Where the contact occurred1

   

0.443

 Home, n (%)

75(65.8)

45 (61.6)

30 (73.2)

 

 Work, n (%)

25 (21.9)

17 (23.3)

8 (19.5)

 

 Another place, n (%)

14 (12.3)

11 (15.1)

3 (7,5)

 

DMARDs withdrawal

76 (36.7)

48 (36.4)

28 (37.3)

0.889

Symptoms

    

 Headache, n (%)

125 (60.4)

83 (62.9)

42 (56.0)

0.331

 Anosmia, n (%)

106 (51.2)

63 (47.7)

43 (57.3)

0.184

 Fever, n (%)

105 (50.7)

69 (52.3)

36 (48.0)

0.554

 Dysgeusia, n (%)

106 (51.2)

67 (50.8)

39 (52.0)

0.864

 Myalgia, n (%)

107 (51.7)

67 (50.8)

40 (53.3)

0.721

 Asthenia, n (%)

101 (48.8)

69 (52.3)

32 (42.7)

0.184

 Cough, n (%)

94 (45.5)

59 (44.7)

35 (46.7)

0.784

 Coryza, n (%),

76 (36.7)

51 (38.6)

25 (33.3)

0.447

 Shortness breath, n (%)

70 (33.8)

49 (37.1)

21 (28.0)

0.182

 Diarrhea, n (%)

66 (31.9)

41 (31.1)

25 (33.3)

0.736

 Arthralgias, n (%)

51 (24.6)

38 (28.8)

13 (17.3)

0.066

 Dizziness, n (%)

38 (18.4)

27 (20.5)

11 (14.,7)

0.301

 Nausea, n (%)

36 (17.4)

25 (18.9)

11 (14.7)

0.436

 Vomiting, n (%)

12 (5.8)

10 (7.6)

2 (2.7)

0.218a

 Skin changes, n (%)

6 (2.9)

3 (4.0)

3 (2.3)

0.670a

 Asymptomatic (only positive lab test), n (%)

8 (3.9)

4 (3.0)

4 (5.3)

0.464a

Lab test for SARS-CoV-22

165 (80.1)

106 (80.3)

59 (79.7)

0.921

 RT-PCR, n (%)

121 (58.5)

83 (62.9)

38 (50.7)

0.087

 Serology (IgM/ IgG), n (%)

24 (11.6)

13 (9,8)

11 (14.7)

0.298

Telemedicine appointment, n (%)

66 (31.8)

42 (32.0)

24 (32.0)

0.985

Hospital care

58 (28.0)

39 (29.5)

19 (25.3)

0.496

 Hospitalization3,4, n (%)

28/58 (48.2)

17/39 (48.7)

10/19 (52.6)

0.729

 Intensive care unit admission3,4, n (%)

10/58 (17.2)

7/39 (18.0)

3/19 (15.8)

1.000b

Mechanical ventilation5, n (%)

7/58 (26.1)

7/39 (18.0)

0/19 (0.0)

0.026a

Hospital lengths stay (days), mean (SD)

13 (12.1)

13.0 (9.0)

13.8 (10.1)

0.626b

  1. p—descriptive level of the chi-square test, Fisher's exact test (a), Student's t (b) or Mann–Whitney test (c); SD: standard deviation
  2. 1Only for cases with contact
  3. 2Only for patients with laboratory confirmed diagnosis
  4. 3Only for patients with hospital care
  5. 4Only for patients with AxSpA and PsA; 1 patient among the two with enteropathic arthritis was hospitalized
  6. 5Only for hospitalized or intensive unit care admission
  7. *3 entheropatic arthritis not described
Back to article page

Advances in Rheumatology

ISSN: 2523-3106